FibroGen, Inc.
FGEN
$8.12
$0.040.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.30M | 7.35M | 7.00M | 29.62M | -47.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.30M | 7.35M | 7.00M | 29.62M | -47.33M |
| Cost of Revenue | 17.55M | 36.30M | 62.85M | 111.26M | 160.70M |
| Gross Profit | -9.25M | -28.96M | -55.86M | -81.64M | -208.03M |
| SG&A Expenses | 28.80M | 32.87M | 40.72M | 49.33M | 36.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.36M | 69.17M | 103.57M | 160.58M | 197.14M |
| Operating Income | -38.06M | -61.83M | -96.57M | -130.96M | -244.47M |
| Income Before Tax | -52.35M | -87.49M | -121.09M | -153.37M | -239.85M |
| Income Tax Expenses | -88.00K | -85.00K | -274.00K | -269.00K | -446.00K |
| Earnings from Continuing Operations | -52.26 | -87.41 | -120.82 | -153.10 | -239.40 |
| Earnings from Discontinued Operations | 267.91M | 85.34M | 110.81M | 105.52M | 78.87M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 215.65M | -2.07M | -10.01M | -47.58M | -121.79M |
| EBIT | -38.06M | -61.83M | -96.57M | -130.96M | -244.47M |
| EBITDA | -36.97M | -60.19M | -94.38M | -128.27M | -240.25M |
| EPS Basic | 53.34 | -0.52 | -2.53 | -12.00 | -30.66 |
| Normalized Basic EPS | -6.86 | -10.47 | -15.82 | -20.98 | -38.87 |
| EPS Diluted | 53.34 | -0.52 | -2.53 | -12.00 | -30.66 |
| Normalized Diluted EPS | -6.86 | -10.47 | -15.82 | -20.98 | -38.87 |
| Average Basic Shares Outstanding | 16.16M | 16.13M | 16.09M | 16.01M | 15.87M |
| Average Diluted Shares Outstanding | 16.16M | 16.13M | 16.09M | 16.01M | 15.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |